

17 β -Hydroxysteroid Dehydrogenase Type 2 Inhibition: Discovery of Selective and Metabolically Stable Compounds Inhibiting both the Human Enzyme and its Murine Ortholog.

Emanuele M. Gargano,¹ Giuseppe Allegretta,² Enrico Perspicace,¹ Angelo Carotti,³ Chris Van Koppen,⁴ Martin Frotscher,¹ Sandrine Marchais-Oberwinkler^{,1} and Rolf W. Hartmann^{*,1,2}*

¹Pharmaceutical and Medicinal Chemistry, Saarland University, Campus C2.3, D-66123 Saarbrücken, Germany.

²Helmholtz Institute for Pharmaceutical Research Saarland (HIPS), Campus C2.3, D-66123 Saarbrücken, Germany.

³Dipartimento Farmaco-Chimico, Università degli Studi di Bari, V. Orabona 4, I-70125 Bari, Italy.

⁴ElexoPharm GmbH, Campus A1.2, D-66123 Saarbrücken, Germany.

- Corresponding author
E-mail: rolf.hartmann(at)helmoltz-hzi.de
s.marchais(at)mx.uni-saarland.de

Abstract

Design and synthesis of a new class of inhibitors for the treatment of osteoporosis and its comparative *h17 β -HSD2* and *m17 β -HSD2* SAR study are described. **17a** is the first compound to show strong inhibition of both *h17 β -HSD2* and *m17 β -HSD2*, intracellular activity, metabolic stability, selectivity toward *h17 β -HSD1*, *m17 β -HSD1* and estrogen receptors α and β as well as appropriate physicochemical properties for oral bioavailability. These properties make it eligible for pre-clinical animal studies, according to FDA guidelines.

Introduction

Osteoporosis is a common, age-related disease, characterized by a systemic impairment of bone mass and microarchitecture, increasing bone fragility and risk of fractures[1]. It has been shown that the drop in 17 β -estradiol (E2) and testosterone (T) levels, occurring with ageing, is the main factor driving the onset and progression of this disease[2]. 17 β -Hydroxysteroid dehydrogenase type 2 (17 β -HSD2) catalyzes the conversion of the highly active E2 and T into the weakly potent 17-ketosteroids estrone (E1) and Δ 4-androstene-3,17-dione (Δ 4-AD), respectively[3]. It is expressed in osteoblastic cells [4], therefore its inhibition can lead to the desired increase of E2 and T levels in the bone tissue and may thus be a novel approach for the treatment of osteoporosis.

Some steroidal[5-7] and non steroidal[8, 9] 17 β -HSD2 inhibitors are already described. In our group we also developed and reported about several classes of non-steroidal 17 β -HSD2 inhibitors[10-14], with a strong inhibition of human 17 β -hydroxysteroid dehydrogenase type 2 (*h17 β -HSD2*) and a good selectivity toward *h17 β -HSD1*. Since *h17 β -HSD1* is the biological counterpart of *h17 β -HSD2*, catalyzing the opposite conversion, selectivity toward this enzyme is an important feature to take into consideration. Potent and selective *h17 β -HSD1* inhibitors have also been described for the treatment of estrogen-dependent diseases[15, 16].

Given that the most commonly used animal model for osteoporosis studies are established in rodents[17, 18], we aimed at the development of new inhibitors displaying a good inhibition of *m17 β -HSD2* and a reasonable selectivity toward *m17 β -HSD1*. In order to meet the FDA requirements for approval of a new drug, a compound must be suitable for studies on both humans and in an appropriate animal model[19]. Therefore, the designed inhibitors should also display *h17 β -HSD2* inhibitory activity and selectivity toward *h17 β -HSD1*. Other characteristics to be implemented are preferably low affinity to the estrogen receptors (ERs) α and β in order to minimize systemic side effects as well as metabolic stability.


Since the 3D-structure for both human and mouse 17 β -HSD2 is up to date not available a ligand based approach was chosen for the design of new inhibitors. A set of *h17 β -HSD2* inhibitors was selected and tested for *m17 β -HSD2* inhibitory activity in order to get insight in the SAR and tracking the lead for the rational design of new inhibitors.

RESULTS AND DISCUSSION

h17 β -HSD2, *h17 β -HSD1*, *m17 β -HSD2* and *m17 β -HSD1* cell-free assays were performed similarly, by incubating enzyme, tritiated substrate, cofactor and inhibitor, according to described procedures[20-23].

As starting point 25 previously described *h17β*-HSD2 inhibitors (Fig. 1), belonging to the 2,5-thiophene amide, 1,3-phenyl amide and 1,4-phenyl amide class[12-14], were tested for *m17β*-HSD2 inhibition, in order to elaborate a comparative SAR and to develop an optimization strategy.

Fig. 1. Previously described *h17β*-HSD2 inhibitors, tested for *m17β*-HSD2 inhibition.



IC₅₀ or percent of inhibition values for both *h17β*-HSD2 and *m17β*-HSD2 are given (Table 1, compounds **1a-2g**, **3a**, **4a-4f**) to facilitate comparison.

Table 1. Inhibition of Human and Mouse 17β-HSD2 by 2,5-Thiophene Amide, 1,3-Phenyl Amide and 1,4-Phenyl Amide Derivatives in a Cell-Free Assay.

Cmp d	R ₁	R ₂	IC ₅₀ (nM) ^a or % inh. at 1 μM ^{a, d}	
			<i>h17β</i> -HSD2 ^b	<i>m17β</i> -HSD2 ^c
1a	3-OMe	3-OMe	68	29%
1b	3-Me	3-Me	52	42%
1c	3-Me	3-OMe	58	30%
1d	2-OMe	3-OMe	490	19%
1e	3-OH	3-OH	33%	n.i.
1f	2-OH	3-OH	410	18%
1g	3-N(Me) ₂	3-OMe	170	40%
1h	3-F	3-OMe	510	n.i.
1i	4-CN	3-OMe	48%	n.i.
1j	2-F, 3-OMe	3-OMe	62	26%
1k	2-F, 3-OMe	3-Me	62	45%
2a	2-F, 3-OMe	3-OH	61	65%
2b	3-OMe	3-	370	16%

		OMe		
2c	3-OH	3-OH	390	26%
2d	4-OH	3-OH	330	35%
2e	3-Me	3-OH	160	45%
2f	3-F	3-OH	330	37%
2g	4-CN	3-OH	n.i.	n.i.
3a	3-Me	3-Me	1100	50%
4a	3-OMe	3-OMe	520	25%
4b	4-OMe	3-OMe	1200	11%
4c	3-OH	3-OH	35%	n.i.
4d	3-OMe	3-OMe	11%	n.i.
4e	3-OH	3-OH	640	29%
4f	4-OH	3-OH	480	22%

^aMean value of at least two determinations, standard deviation less than 20%. ^bHuman placental microsomal fraction, substrate E2 [500 nM], cofactor NAD⁺ [1500 μM]. ^cMouse liver microsomal fraction, substrate E2 [500 nM], cofactor NAD⁺ [1500 μM]. ^dn.i.: no inhibition, i.e., inhibition ≤10%.

In the 2,5-thiophene amide class (compounds **1a-2g**), *h17β*-HSD2 inhibitors[13, 14], a broad range of inhibitory activities was detected, depending on the substitution pattern; the most active compounds show IC₅₀ values around 60 nM (Table 1). Conversely, the inhibitory activity towards *m17β*-HSD2 was only marginally affected by these changes (inhibitory activity around 30% at 1 μM). Only compound **2a** shows a more pronounced *m17β*-HSD2 inhibition combined with good inhibition of the human enzyme (65% at 1 μM and IC₅₀ = 61 nM). Unfortunately, compound **2a** turned out to be metabolically very unstable, with a half-life of only 4 minutes in the human liver S9 fraction[13]. In a further screening, all the tested 2,5-thiophene amide displayed a high metabolic instability [13].


It is striking that neither the nature of substituents on ring A and C or their substitution pattern does appear to exert an effect on *m17β*-HSD2 inhibition, whereas it is decisive for the *h17β*-HSD2 one. This result suggests that the inhibitors in this class are likely to have different binding modes in the two enzyme isoforms.

Exchange of the central thiophene by a 1,3-disubstituted phenyl led to compounds **4a-4c** for n = 0 and **4d-4f** for n = 1, with weak inhibitory activity towards both the human and the mouse enzyme (Table 1).

In contrast, compound **3a** (Table 1), bearing a 1,4-disubstituted phenyl moiety as central ring, shows moderate inhibition of both *h17β*-HSD2 and *m17β*-HSD2 and also revealed exceptional metabolic stability in the human liver S9 fraction, with a half-life time >120 minutes[13]. It was therefore

taken as starting point for the design of a small library of inhibitors where the substitution pattern and the physicochemical nature of substituents on the A and C rings was varied (Fig. 2). Compounds **25a** and **25** were also synthesized to investigate the effect of the methylene linker between the amide function and the C ring.


Fig. 2. Chemical Structures of the Designed Compounds



The synthesis of the 1,4-phenyl derivatives **5a-23a**, **25a**, **7** and **25**, depicted in Fig. 3, was accomplished following a two- or three-step reaction pathway.

Fig. 3. Synthesis of 1,4-Phenyl Derivatives 5a-23a, 25a, 7.

Reagents and conditions: (i) Et_3N , CH_2Cl_2 , room temperature, overnight; (ii) $\text{DME}/\text{EtOH}/\text{H}_2\text{O}$ (1:1:1), Cs_2CO_3 , $\text{Pd}(\text{PPh}_3)_4$, microwave irradiation (150°C , 150W, 20 min); (iii) $\text{BF}_3 \cdot \text{SMe}_2$, CH_2Cl_2 , room temperature, overnight.




First, amidation was carried out by reaction of the commercially available 4-bromobenzoyl chloride **5d** with substituted anilines **5c** or with the 1-(3-methoxyphenyl)-*N*-methylmethanamine **25c** using standard conditions (method A: triethylamine, dichloromethane, from 0 °C to room temperature, overnight) affording the brominated intermediates **5b**, **6b** and **11b** in almost quantitative yields. Subsequently, Suzuki coupling (Method B) using tetrakis(triphenylphosphine)palladium and cesium carbonate in a mixture of DME/EtOH/H₂O (1:1:1,3 mL) as solvent and microwave irradiation (150°C, 150 W for 20 minutes), provided the biphenyl derivatives **5a-21a** and **25a**, and the 1,3-benzodioxole derivatives **22a** and **23a** in good yields. Compounds **7a** and **25a** were submitted to ether cleavage using boron trifluoride-dimethyl sulfide complex, yielding the hydroxylated molecules **7** and **25**.

The synthesis of the retroamide **24a**, displayed in Fig. 4, follows a two-step procedure.

Fig. 4. Synthesis of 1,4-Phenyl Retroamide Derivative **24a**.

Reagents and conditions: (i) Et₃N, CH₂Cl₂, room temperature, overnight; (ii) DME/EtOH/H₂O (1:1:1), Cs₂CO₃, Pd(PPh₃)₄, microwave irradiation (150°C, 150W, 20 min).



First the commercially available 3-methoxybenzoyl chloride **24c** was reacted with 4-bromo-*N*-methyl aniline **24d** according to method A and afforded the brominated intermediate **24b** with 70% yield. Subsequently, Suzuki coupling following method B afforded compound **24a** in 68% yield.

Compounds **5a-25a**, **7** and **25** were tested for *h17β*-HSD2, *m17β*-HSD2 and *h17β*-HSD1 inhibition (Table 2, results expressed as percentage of inhibition or IC₅₀ value).

Table 2. Inhibition of *h17β*-HSD2, *m17β*-HSD2 and *h17β*-HSD1 by Biphenyl Amide Derivatives with Different Substitution Patterns on the A and C Rings in Cell-Free System.

Cmpd	R ₁	R ₂	IC ₅₀ (nM) ^a or % inh. at 1 μM ^{a, c}		s. f. ^{d, f}	IC ₅₀ (nM) ^a or % inh. at 1 μM ^{a, c}
			<i>h17β</i> -HSD2 ^b	<i>h17β</i> -HSD1 ^c		<i>m17β</i> -HSD2 ^{f, g}
3a	3-Me	3-Me	1100	11500	10	50%
5a	3-OMe	3-Me	44%	n.i.	n.d.	56%
6a	3-Me	3-OMe	260	6400	25	260
7a	3-OMe	3-OMe	330	6400	20	290
8a	-H	3-OMe	51%	22%	n.d.	48%
9a	2-OMe	3-OMe	50%	n.i.	n.d.	33%
10a	4-OMe	3-OMe	710	27000	38	66%
11a	3-OMe	4-OMe	27%	n.i.	n.d.	58%
12a	4-OMe	4-OMe	19%	n.i.	n.d.	62%
7	3-OH	3-OH	36%	15%	n.d.	42%
13a	3-F	3-OMe	1000	8000	8	57%
14a	3-Cl	3-OMe	950	12600	13	73%
15a	3-N(Me) ₂	3-OMe	650	5000	8	67%
16a	3-OMe, 4-OMe	3-OMe	520	85500	164	52%
17a	3-Me, 4-Me	3-OMe	300	13300	44	140
18a	3-F, 4-F	3-OMe	31%	n.i.	n.d.	n.d.
19a	2-F, 3-OMe	3-OMe	64%	35%	n.d.	67%
20a	2-F, 3-Me	3-OMe	460	11300	24	48%
21a	2-F, 3-Me	3-Me	330	3710	11	56%
22a	-	3-OMe	51%	n.i.	n.d.	56%
23a	-	3-Me	560	10900	20	70%
24a	-	-	11%	n.i.	n.d.	n.d.
25a	2-F, 3Me	3-OMe	310	87000	283	43%
25	2-F, 3-Me	3-OH	260	31000	118	190

^aMean value of at least two determinations, standard deviation less than 20% except for 11a (*h*HSD2): 26%, 7(*h*HSD1):25%,. ^bHuman placental, microsomal fraction, substrate E2[500 nM], cofactor NAD⁺[1500 μM]. ^cHuman placental, cytosolic fraction, substrate E1[500 nM], cofactor NADH[500 μM]. ^ds.f. (selectivity factor)=IC₅₀(17β-HSD1)/IC₅₀(17β-HSD2). ^en.i.: no inhibition

(inhibition of <10%).^fn.d.: not determined. ^gMouse liver microsomal fraction, substrate E2 [500 nM], cofactor NAD⁺ [1500 μM].

Compounds **18a** and **24a** were not tested for inhibition of *m17β*-HSD2, due to their low inhibitory activity towards the human enzyme. Among the different synthesized 1,4-biphenyl amides without methylene linker (n=0, Table 2, compounds **5a-21a**), the best *h17β*-HSD2 inhibitory activity and selectivity toward *h17β*-HSD1 was achieved for compounds **6a**, **7a** and **17a** (Table 2, IC₅₀ values between 260 and 330nM, s.f. between 20 and 44), showing that a 3-OMe-group on ring C in combination with either a 3-OMe- or a 3-Me-group on ring A leads to a maximum in potency and selectivity in this series of compounds.

The presence of a methyl group in 4-position of ring A is tolerated by the *h17β*-HSD2 (compound **17a**, IC₅₀ = 310nM) and increases the selectivity toward *h17β*-HSD1 (**17a**: s.f. 44; **6a**: s.f. 25). In contrast, compound **16a** bearing a 3,4-dimethoxy substituted A ring displays a slight decrease in *h17β*-HSD2 inhibitory activity if compared to the corresponding compound **7a** with only one methoxy group on that ring. The rigidification of the two methoxy substituents by the synthesis of a 1,3-benzodioxole ring (compounds **22a** and **23a**) could not overcome the drop in potency. Compounds **6a**, **7a** and **17a** displayed the strongest *m17β*-HSD2 inhibitory activity (IC₅₀ = 260, 290 and 140 nM, respectively).

In general, the introduction of methyl- or methoxy-groups, especially in the 3-positions of rings A and B, had a positive impact on inhibitory activity, which is similar for both 17β-HSD2 isoforms (Table 2). Therefore, inhibitors belonging to the 1,4-phenyl class are likely to bind in a conserved area common to both enzyme, in contrast to the 2,5-thiophene amide class. As 17β-HSD2 belongs to the SDR superfamily, characterized by the conserved Rossmann fold and catalytic triad[24], it is possible that these inhibitors bind in or very close to these region.

Compounds with a methylene linker **25a** and **25** (Table 2), showed *h17β*-HSD2 inhibitory activity in the same order of magnitude as the corresponding derivative **20a** lacking the methylene group, but displayed improved selectivities over *h17β*-HSD1. In contrast to what was observed for human 17β-HSD2, compounds **25a** and **25** showed a significant difference in terms of *m17β*-HSD2 inhibition, indicating that the hydroxy group of compound **25** might function as H-bond donor in the interaction with the enzyme.

The most potent *m17β*-HSD2 inhibitors **6a-8a**, **10a**, **14a**, **15a**, **17a**, **19a**, **21a**, **23a** and **25** were also tested for their *m17β*-HSD1 inhibitory activity. None of the tested compounds showed any inhibition of *m17β*-HSD1 at a concentration of 1 μM, indicating a significant selectivity toward this enzyme.

The inhibitory activity of compounds **6a**, **17a** and **25** was also evaluated in the human mammary cell line MDA-MB-231 containing endogenous 17β-HSD2 (Table 3). The compounds were tested at 250 nM and 1250 nM, representing approximately the IC₅₀ observed in the cell-free assay, and its 5-fold value. As displayed in Table 3, all three compounds showed an inhibition between 60% and 67% at the lower concentration and approximately 90% inhibition at the higher concentration, indicating that the inhibitors can permeate the membrane and are able to inhibit the enzyme in a concentration dependent manner.

Table 3. Human 17 β -HSD2 Cellular Inhibition of Compounds 6a, 17a and 25.

Cmpd	% inh ^b HSD2 ^a at 250 nM	% inh ^b HSD2 ^a at 1250 nM
6a	60%	87%
17a	66%	90%
25	67%	88%

^aMDA-MB-231 cell line, substrate E2[200 nM]. ^bMean value of two determinations, standard deviation less than 15%.

Compounds **6a**, **7a**, **17a**, **21a**, **25a** and **25** were tested for their affinity toward the ERs α and β according to described methods[25] (assay details are available in the Supporting Information). Even when applied in a 1000-fold excess relative to E2, no inhibitor was able to displace more than 20% of the steroid from the corresponding receptor, indicating a very low binding affinity to the ERs.

The metabolic stabilities of the most active compounds **6a**, **17a** and **25** were evaluated using human liver microsomes (S9 fraction). In addition, compounds **5a**, **14a**, **20a** and **25a** were also tested in order to allow a structure-metabolic stability relationship analysis (Table 4, assay details are available in the Supporting Information). All compounds, except **25**, revealed a very high stability, which was not influenced by the nature of the substituents. Compound **25**, exhibiting a short half-life, bears a hydroxy group, potentially susceptible to phase II metabolism. Interestingly, all the tested inhibitors from the 1,4-phenyl amide class, for n= 0, demonstrated high metabolic stability, which seemingly constitutes a positive feature of the whole class. As species differences for the metabolism of drugs that are not or only partly metabolized are usually small [26], sufficient metabolic stability in species other than human can be anticipated.

Table 4. Half-life in Human Liver Microsomes S9 Fraction of Representative Compounds 3a, 5a, 6a, 14a, 17a, 20a, 25a and 25.

Cmpd	R ₁	R ₂	Inhibitor ^c t _{1/2} (min) ^{a,b}
3a	3-Me	3-Me	>120
5a	3-OMe	3-Me	116
6a	3-Me	3-OMe	106
14a	3-Cl	3-OMe	82
17a	3-Me,4-Me	3-OMe	107
20a	2-F, 3-Me	3-OMe	104
25a	2-F, 3-Me	3-OMe	103
25	2-F, 3-Me	3-OH	6

^aMean of at least two determinations, standard deviation less than 25%. ^b1 mg/ml pooled mammalian liver S9 fraction (BD Gentest), 2 mM NADPH regenerating system, 1 mM UDPGA and 0.1 mM PAPS at 37°C for 0, 5, 15 and 60 minutes. ^cInhibitor tested at a final concentration of 1 μ M.

CONCLUSION

The aim of this work was the design of a compound, which should be suitable for application in both an animal model of osteoporosis and in humans. We report here the discovery of compound **17a**, which is the first to show an appropriate profile for this purpose, with strong inhibition of both human and mouse 17β -HSD2 and selectivity toward the respective type 1 enzymes and the ERs. It also displayed good cellular inhibitory activity, high metabolic stability and good physicochemical parameters (MW= 345 and cLogP = 4.75) predictor for good oral bio-availability[27]. A comparative SAR study for *h* 17β -HSD2 and *m* 17β -HSD2 is also described for the 1,4-phenyl and the 2,5-thiophene classes of inhibitors, revealing that only compounds belonging to the first series similarly inhibit the two enzymes, probably through a similar binding mode. The species specific characterization of the thiophene and the phenyl derivatives pointed out the superiority of the latter class of inhibitors, which is able to equally inhibit the two isoenzymes and additionally displays a high metabolic stability. *In vivo* assays in a mouse osteoporosis model will be carried out soon and the results reported in due course in a specialized journal dealing with bone diseases.

Materials and Methods

Chemical Methods

Chemical names follow IUPAC nomenclature. Starting materials were purchased from Aldrich, Acros, Combi-Blocks or Fluorochem and were used without purification. Column chromatography was performed on silica gel (70-200 μ m) and reaction progress was monitored by TLC on Alugram SIL G/UV254 (Macherey-Nagel). Visualization was accomplished with UV light. ^1H NMR and ^{13}C NMR spectra were measured on a Bruker AM500 spectrometer (at 500 MHz and 125 MHz, respectively) at 300 K and on Bruker Fourier 300 (at 300 MHz and 75 MHz, respectively) at 300K. Chemical shifts are reported in δ (parts per million: ppm), by reference to the hydrogenated residues of deuteriated solvent as internal standard: 2.05 ppm (^1H NMR) and 29.8 and 206.3 ppm (^{13}C NMR) for CD_3COCD_3 , 7.26 ppm (^1H NMR) and 77.0 ppm (^{13}C NMR) for CDCl_3 . Signals are described as br (broad), s (singlet), d (doublet), t (triplet), dd (doublet of doublets), ddd (doublet of doublet of doublets), dt (doublet of triplets) and m (multiplet). All coupling constants (J) are given in Hertz (Hz).

Melting points (mp) were measured in open capillaries on a Stuart Scientific SMP3 apparatus and are uncorrected.

Mass spectrometry was performed on a TSQ Quantum (ThermoFisher, Dreieich, Germany). The triple quadrupole mass spectrometer was equipped with an electrospray interface (ESI). The purity of the compounds was assessed by LC/MS. The Surveyor-LC-system consisted of a pump, an auto sampler, and a PDA detector. The system was operated by the standard software Xcalibur. A RP C18 NUCLEODUR 100-5 (3 mm) column (Macherey-Nagel GmbH, Dühren, Germany) was used as stationary phase. All solvents were HPLC grade. In a gradient run the percentage of acetonitrile (containing 0.1 % trifluoroacetic acid) was increased from an initial concentration of 0 % at 0 min to 100 % at 15 min and kept at 100 % for 5 min. The injection volume was 15 μ L and flow rate was set to 800 μ L/min. MS analysis was carried out at a needle voltage of 3000 V and a capillary

temperature of 350 °C. Mass spectra were acquired in positive mode from 100 to 1000 m/z and UV spectra were recorded at the wave length of 254 nm and in some cases at 360 nm.

All microwave irradiation experiments were carried out in a 507 CEM-Discover microwave apparatus.

All tested compounds exhibited $\geq 95\%$ chemical purity as measured by LC/MS.

The following compounds were prepared according to previously described procedures: 4-bromo-*N*-methyl-*N*-(*m*-tolyl)benzamide **7a**[13].

Method A, general procedure for amide formation

To a solution of bromobenzoylchloride (2 mmol) was added the corresponding *N*-methylanilin (2 mmol) followed by Et₃N (2 mmol) in CH₂Cl₂ (10 mL) at 0°C. After a few minutes, the ice bath was removed and the reaction mixture was warmed up to room temperature and stirred at room temperature overnight. The reaction mixture was extracted twice with CH₂Cl₂ (2 × 15 mL). The organic layer was dried over MgSO₄, filtered and the solution was concentrated under reduced pressure. The residue was purified by silica gel column chromatography using hexanes and EtOAc as eluent or by trituration in a mixture of diethyl ether / petroleum ether to afford the desired compound.

Method B, general procedure for Suzuki-Miyaura coupling

In a sealed tube the previously prepared bromo-*N*-heteroarylcarboxamide derivative (1 eq.) was introduced, followed by the corresponding boronic acid (1.5 eq.), cesium carbonate (3 eq.), tetrakis(triphenylphosphine)palladium (0.02 eq.) and a mixture of DME/EtOH/H₂O (1:1:1, v:v:v, 3 mL) as solvent. The reactor was flushed with N₂ and submitted to microwave irradiation (150°C, 150 W) for 20 minutes. After cooling to room temperature, a mixture of EtOAc/H₂O (1:1, v:v, 2 mL) was added to stop the reaction. The aqueous layer was extracted with EtOAc (3 × 10 mL). The organic layer was washed once with brine and once with water, dried over MgSO₄, filtered and the solution was concentrated under reduced pressure. The residue was purified by column chromatography using hexanes and EtOAc as eluent to afford the desired compound.

Detailed synthesis procedures of the compounds

4-Bromo-*N*-(4-methoxyphenyl)-*N*-methylbenzamide (11b) The title compound was prepared by reaction of 4-bromobenzoyl chloride **5c** (1272 mg, 5.8mmol) and 4-methoxy-*N*-methylaniline **11d** (400 mg, 2.9mmol) according to method A. The residue was purified by silica gel column chromatography (hexanes/EtOAc80:20) to afford the desired product as yellow solid (932 mg, 99 %). C₁₅H₁₄BrNO₂; MW 320; mp: 61 – 62°C; MS (ESI) 320, 322 [M]⁺; IR (cm⁻¹) 1635, 2840, 2850, 2917; ¹H NMR (C₂D₆CO, 500 MHz) δ (ppm) 3.36 (s, 3H), 3.74 (s, 3H), 6.82 (d, *J* = 9.0 Hz, 2H), 7.09 (d, *J* = 9.0 Hz, 2H), 7.23 (d, *J* = 8.0 Hz, 2H), 7.38 (d, *J* = 8.0 Hz, 2H); ¹³C NMR (C₂D₆CO, 125 MHz) δ (ppm) 38.5, 55.7, 115.2, 123.7, 129.3, 131.4, 131.6, 137.1, 138.6, 159.1, 169.5.

4-Bromo-*N*-(3-methoxyphenyl)-*N*-methylbenzamide (6b) The title compound was prepared by reaction of 4-bromobenzoyl chloride **5c** (1272 mg, 5.8mmol) and 3-methoxy-*N*-methylaniline **6d** (400 mg, 2.9mmol) according to method A. The residue was purified by silica gel column

chromatography (hexanes/EtOAc80:20) to afford the desired product as yellow solid (935 mg, quantitative). C₁₅H₁₄BrNO₂; MW 320; mp: 98 – 100°C; MS (ESI) 320, 322 [M]⁺; IR (cm⁻¹) 1638, 2840, 2945, 3012; ¹H NMR (C₂D₆CO, 500 MHz) δ (ppm) 3.40 (s, 3H), 3.71 (s, 3H), 6.70 – 6.72 (m, 1H), 6.74 – 6.78 (m, 2), 7.17 (t, *J* = 8.0 Hz, 1H), 7.26 – 7.28 (m, 2H), 7.39 – 7.41 (m, 2H); ¹³C NMR (C₂D₆CO, 125 MHz) δ (ppm) 38.2, 55.7, 113.2, 113.8, 120.2, 123.9, 130.7, 131.3, 131.6, 137.0, 147.0, 161.2, 169.4.

4-Bromo-*N*-methyl-*N*-(*m*-tolyl)benzamide (5b) The title compound was prepared by reaction of 4-bromobenzoyl chloride **5c** (724 mg, 3.3mmol) and *N*-methyl-*m*-toluidine **5d** (200 mg, 1.6mmol) according to method A. The residue was purified by silica gel column chromatography (hexanes/EtOAc80:20) to afford the desired product as white solid (500 mg, 99%). C₁₅H₁₄BrNO; MW 304; mp: 90 – 92 °C; MS (ESI) 304, 306 [M]⁺; IR (cm⁻¹) 1586, 1638, 2853, 2923, 3058; ¹H NMR (C₂D₆CO, 300 MHz) δ (ppm) 2.24 (s, 3H), 3.39 (s, 3H), 6.90 – 6.93 (d, *J* = 8.0Hz, 1H), 6.99 – 7.05 (m, 2H), 7.14 (t, *J* = 8.0 Hz, 1H), 7.23 – 7.26 (m, 2H), 7.37 – 7.40 (m, 2H); ¹³C NMR (C₂D₆CO, 75 MHz) δ (ppm) 21.2, 38.4, 123.9, 125.2, 128.1, 128.5, 129.8, 131.4, 131.6, 137.0, 140.0, 145.8, 169.4.

4-Bromo-*N*-(3-methoxybenzyl)-*N*-methylbenzamide (25b) The title compound was prepared by reaction of 4-bromobenzoyl chloride **5c** (579 mg, 2.6mmol) and 3-methoxy-*N*-methylbenzylamine **25d** (200 mg, 1.3mmol) according to method A. The residue was purified by silica gel column chromatography (hexanes/EtOAc80:20) to afford the desired product as yellow oil (430 mg, 97 %). C₁₆H₁₆BrNO₂; MW 334; MS (ESI) 334, 336 [M]⁺; IR (cm⁻¹) 1630, 2834, 2923; ¹H NMR (C₂D₆CO, 500 MHz) δ (ppm) 2.91 (s, 3H), 3.79 (s, 3H), 4.52 – 4.70 (m, 2H), 6.76-6.80 (m, 1H), 6.86 (dd, *J* = 8.8 Hz, 5Hz, 1H), 6.95 (s, 1H), 7.28 (t, *J* = 8.0 Hz, 1H), 7.44 (d, *J* = 7.6 Hz, 2H), 7.62 (s, 2H); ¹³C NMR (C₂D₆CO, 125 MHz) δ (ppm) 37.2, 51.0, 55.5, 113.3, 113.6, 114.4, 119.7, 121.0, 123.9, 129.9, 130.5, 132.3, 137.0, 161.1.

***N*-(4-bromophenyl)-3-methoxy-*N*-methylbenzamide (24b)** The title compound was prepared by reaction of 3-methoxybenzoyl chloride **24c** (336 mg, 2.0mmol) and 4-bromo-*N*-methylaniline **24d** (367 mg, 2.0mmol) according to method A. The residue was purified by silica gel column chromatography (hexanes/EtOAc80:20) to afford the desired product as white solid (440 mg, 70 %). C₁₅H₁₄BrNO₂; MW 320; mp: 97 – 100°C; MS (ESI) 320, 322 [M]⁺; IR (cm⁻¹) 1634, 2834, 2929, 3009; ¹H NMR (C₂D₆CO, 300 MHz) δ (ppm) 3.41 (s, 3H), 3.69 (s, 3H), 6.84 – 6.88 (m, 3H), 7.12 – 7.17 (m, 3H), 7.44 – 7.47 (m, 2H); ¹³C NMR (C₂D₆CO, 75 MHz) δ (ppm) 38.3, 55.6, 114.8, 116.3, 120.1, 121.7, 129.8, 130.0, 133.1, 138.8, 145.7, 160.1, 170.3.

***N*-(3-methoxyphenyl)-*N*-methyl-[1,1'-biphenyl]-4-carboxamide (8a)** The title compound was prepared by reaction of 4-bromo-*N*-(3-methoxyphenyl)-*N*-methylbenzamide (**6b**) (80 mg, 0.25mmol), phenylboronic acid (40 mg, 0.33mmol), cesium carbonate (244 mg, 0.75mmol) and tetrakis(triphenylphosphine) palladium (0.02 eq., 6 mg) in DME/EtOH/H₂O (1/1/1, 3 mL) according to method B. The residue was purified by silica gel column chromatography (hexanes/EtOAc70:30) to afford the desired product as yellow solid (77 mg, 97 %). C₂₁H₁₉NO₂; MW 317; mp: 102 – 104°C; MS (ESI) 318 [M+H]⁺; IR (cm⁻¹) 1588, 1636, 2831, 2917, 2960, 3040; ¹H NMR (C₂D₆CO, 300 MHz) δ (ppm) 3.44 (s, 3H), 3.70 (s, 3H), 6.72 – 6.77 (m, 2H), 6.80 (t, *J* = 2 Hz, 1H), 7.17 (t, *J* = 8 Hz, 1H), 7.33 – 7.37 (s, 1H), 7.41 – 7.46 (m, 4H), 7.51 – 7.54 (m, 2H), 7.60 – 7.63 (m, 2H); ¹³C

NMR (C₂D₆CO, 75 MHz) δ (ppm) 38.4, 55.7, 113.0, 113.8, 120.1, 126.9, 127.7, 128.6, 129.8, 130.1, 130.6, 136.7, 140.8, 142.6, 147.4, 161.2, 170.2.

2'-Methoxy-*N*-(3-methoxyphenyl)-*N*-methyl-[1,1'-biphenyl]-4-carboxamide (9a) The title compound was prepared by reaction of 4-bromo-*N*-(3-methoxyphenyl)-*N*-methylbenzamide (**6b**) (112 mg, 0.35mmol), 2-methoxyphenylboronic acid (70 mg, 0.46mmol), cesium carbonate (342 mg, 1.05mmol) and tetrakis(triphenylphosphine) palladium (0.02 eq., 8 mg) in DME/EtOH/H₂O (1/1/1, 3 mL) according to method B. The residue was purified by silica gel column chromatography (hexanes/EtOAc70:30) to afford the desired product as colorless oil (113 mg, 93 %). C₂₂H₂₁NO₃; MW 347; MS (ESI) 348 [M+H]⁺; IR (cm⁻¹) 1597, 1640, 2837, 2939; ¹H NMR (C₂D₆CO, 500 MHz) δ (ppm) 3.44 (s, 3H), 3.69 (s, 3H), 3.77 (s, 3H), 6.73 – 6.78 (m, 3H), 6.99 (dt, *J* = 1.0, 7.3 Hz, 1H), 7.07 (dd, *J* = 1.0, 8.3 Hz, 1H), 7.18 (dt, *J* = 1.0, 7.5 Hz, 1H), 7.24 (dd, *J* = 2.0, 7.5 Hz, 1H), 7.30 – 7.34 (m, 1H), 7.35 – 7.39 (m, 4H); ¹³C NMR (C₂D₆CO, 125 MHz) δ (ppm) 38.4, 55.6, 55.9, 112.5, 113.0, 113.7, 120.0, 121.7, 129.1, 129.5, 130.0, 130.4, 130.6, 131.3, 136.0, 140.7, 147.4, 157.5, 161.1, 170.4.

3'-Methoxy-*N*-(3-methoxyphenyl)-*N*-methyl-[1,1'-biphenyl]-4-carboxamide (7a) The title compound was prepared by reaction of 4-bromo-*N*-(3-methoxyphenyl)-*N*-methylbenzamide (**6b**) (81 mg, 0.25mmol), 3-methoxyphenylboronic acid (46 mg, 0.3mmol), cesium carbonate (247 mg, 0.75mmol) and tetrakis(triphenylphosphine) palladium (0.02 eq., 6 mg) in DME/EtOH/H₂O (1/1/1, 3 mL) according to method B. The residue was purified by silica gel column chromatography (hexanes/EtOAc70:30) to afford the desired product as white solid (74 mg, 85 %). C₂₂H₂₁NO₃; MW 347; mp: 131– 134°C; MS (ESI) 348 [M+H]⁺; IR (cm⁻¹) 1582, 1635, 2837, 2941, 2963; ¹H NMR (C₂D₆CO, 500 MHz) δ (ppm) 3.43 (s, 3H), 3.70 (s, 3H), 3.84 (s, 3H), 6.73 – 6.76 (m, 2H), 6.80 – 6.81 (m, 1H), 6.92(ddd, *J* = 1.0, 2.0, 8.0 Hz, 1H), 7.14 – 7.19 (m, 3H), 7.32 – 7.35 (m, 1H), 7.41 – 7.42 (m, 2H), 7.51 – 7.53 (m, 2H); ¹³C NMR (C₂D₆CO, 125 MHz) δ (ppm) 38.4, 55.6, 55.7, 113.0, 113.1, 113.8, 114.3, 120.0, 120.1, 126.9, 130.0, 130.6, 130.8, 136.8, 142.2, 142.5, 147.37, 147.38, 161.2, 170.2.

3'-Hydroxy-*N*-(3-hydroxyphenyl)-*N*-methyl-[1,1'-biphenyl]-4-carboxamide (7) To a solution of 3'-methoxy-*N*-(3-methoxyphenyl)-*N*-methyl-[1,1'-biphenyl]-4-carboxamide (**7a**) (100 mg, 0.29mmol) in CH₂Cl₂ (10 mL) was added trifluorobromine dimethyl sulphide complex BF₃.SMe₂ (0.36 mL, 3.46 mM) at room temperature. The reaction mixture was stirred overnight. The reaction was quenched with MeOH (10 mL). The solvent was removed under reduced pressure at 25°C. Water was added to dissolve inorganic salts and the precipitate was filtered off and triturated with diethyl ether to afford the desired product as white solid (80 mg, 87 %). C₂₀H₁₇NO₃; MW 319; mp: 168 – 171°C; MS (ESI) 320[M+H]⁺; IR (cm⁻¹) 1589, 3191; ¹H NMR (C₂D₆CO, 300 MHz) δ (ppm) 3.42 (s, 3H), 6.64 – 6.68 (m, 3H), 6.82 – 6.86 (m, 1H), 7.07 – 7.12 (m, 3H), 7.26 (t, *J* = 8.0 Hz, 1H), 7.39 – 7.44 (m, 2H), 7.47 – 7.49 (m, 2H), 8.42 (s, 1H), 8.48 (s, 1H); ¹³C NMR (C₂D₆CO, 75 MHz) δ (ppm) 38.4, 114.4, 114.6, 115.0, 115.6, 119.0, 119.1, 126.8, 130.1, 130.7, 130.8, 136.6, 142.3, 142.7, 147.4, 158.8, 158.9, 170.1.

4'-Methoxy-*N*-(3-methoxyphenyl)-*N*-methyl-[1,1'-biphenyl]-4-carboxamide (10a) The title compound was prepared by reaction of 4-bromo-*N*-(3-methoxyphenyl)-*N*-methylbenzamide (**6b**) (123 mg, 0.38mmol), 4-methoxyphenylboronic acid (75 mg, 0.49mmol), cesium carbonate (371

mg, 1.14mmol) and tetrakis(triphenyl)phosphine palladium (0.02 eq., 9 mg) in DME/EtOH/H₂O (1/1/1, 3 mL) according to method B. The residue was purified by silica gel column chromatography (hexanes/EtOAc80:20) to afford the desired product as white solid (70 mg, 53 %). C₂₂H₂₁NO₃; MW 347; mp: 128 – 130°C; MS (ESI) 348 [M+H]⁺; IR (cm⁻¹) 1601, 1625, 2840, 2935, 2963; ¹H NMR (C₂D₆CO, 500 MHz) δ (ppm) 3.43 (s, 3H), 3.70 (s, 3H), 3.82(s, 3H), 6.72 – 6.75 (m, 2H), 6.78 – 6.79 (m, 1H), 6.98 (d, *J* = 2.3 Hz, 1H), 7.00 (d, *J* = 2.3 Hz, 1H), 7.15 – 7.18 (m, 1H), 7.37 – 7.40 (m, 2H), 7.46 – 7.48 (m, 2H), 7.55 – 7.58 (m, 2H); ¹³C NMR (C₂D₆CO, 125 MHz) δ (ppm) 38.4, 55.6, 55.7, 112.9, 113.8, 115.2, 120.1, 126.3, 128.8, 130.1, 130.6, 130.1, 135.9, 142.4, 147.5, 160.7, 161.2, 170.3.

3'-Fluoro-*N*-(3-methoxyphenyl)-*N*-methyl-[1,1'-biphenyl]-4-carboxamide (13a) The title compound was prepared by reaction of 4-bromo-*N*-(3-methoxyphenyl)-*N*-methylbenzamide (**6b**) (100 mg, 0.31mmol), 3-fluorophenylboronic acid (57 mg, 0.41mmol), cesium carbonate (303 mg, 0.93mmol) and tetrakis(triphenyl)phosphine palladium (0.02 eq., 7 mg) in DME/EtOH/H₂O (1/1/1, 3 mL) according to method B. The residue was purified by silica gel column chromatography (hexanes/EtOAc70:30) to afford the desired product as yellow solid (91 mg, 89 %). C₂₁H₁₈FNO₂; MW 335; mp: 97 – 100°C; MS (ESI) 336 [M+H]⁺; IR (cm⁻¹) 1587, 1637, 2834, 2923, 2960; ¹H NMR (C₂D₆CO, 300 MHz) δ (ppm) 3.44 (s, 3H), 3.71 (s, 3H), 6.73 – 6.77 (m, 2H), 6.80 – 6.81 (m, 1H), 7.09 – 7.21 (m, 2H), 7.36 – 7.50 (m, 5H), 7.55 – 7.57 (m, 2H); ¹³C NMR (C₂D₆CO, 75 MHz) δ (ppm) 38.4, 55.8, 113.1, 113.9, 114.3, 114.6, 115.2, 115.4, 120.2, 123.7, 127.1, 130.2, 130.8, 131.6, 131.8, 137.4, 141.2, 143.3, 143.4, 147.4, 161.3, 162.6, 165.8, 170.1.

3'-Chloro-*N*-(3-methoxyphenyl)-*N*-methyl-[1,1'-biphenyl]-4-carboxamide (14a) The title compound was prepared by reaction of 4-bromo-*N*-(3-methoxyphenyl)-*N*-methylbenzamide (**6b**) (80 mg, 0.25mmol), 3-chlorophenylboronic acid (52 mg, 0.33mmol), cesium carbonate (244 mg, 0.75mmol) and tetrakis(triphenyl)phosphine palladium (0.02 eq., 6 mg) in DME/EtOH/H₂O (1/1/1, 3 mL) according to method B. The residue was purified by silica gel column chromatography (hexanes/EtOAc70:30) to afford the desired product as colorless oil (47 mg, 53 %). C₂₁H₁₈ClNO₂; MW 352; MS (ESI) 352, 354 [M]⁺; IR (cm⁻¹) 1594, 1639, 2837, 2938; ¹H NMR (C₂D₆CO, 500 MHz) δ (ppm) 3.43 (s, 3H), 3.70 (s, 3H), 6.73 – 6.76 (m, 2H), 6.80 – 6.81 (m, 1H), 7.17 (t, *J* = 8 Hz, 1H), 7.38 – 7.40 (m, 1H), 7.43 – 7.47 (m, 3H), 7.54 – 7.59 (m, 3H), 7.63 – 7.64 (m, 1H); ¹³C NMR (C₂D₆CO, 125 MHz) δ (ppm) 38.3, 55.7, 113.1, 113.8, 120.2, 126.3, 127.0, 127.6, 128.5, 130.1, 130.7, 131.4, 135.3, 137.4, 141.0, 142.9, 147.3, 161.2, 170.0.

***N*-(3-methoxyphenyl)-*N*,3'-dimethyl-[1,1'-biphenyl]-4-carboxamide (6a)** The title compound was prepared by reaction of 4-bromo-*N*-(3-methoxyphenyl)-*N*-methylbenzamide (**6b**) (77 mg, 0.24mmol), 3-methylphenylboronic acid (42 mg, 0.31mmol), cesium carbonate (235 mg, 0.72mmol) and tetrakis(triphenyl)phosphine palladium (0.02 eq., 6 mg) in DME/EtOH/H₂O (1/1/1, 3 mL) according to method B. The residue was purified by silica gel column chromatography (hexanes/EtOAc70:30) to afford the desired product as colorless oil (56 mg, 71 %). C₂₂H₂₁NO₂; MW 331; MS (ESI) 332 [M+H]⁺; IR (cm⁻¹) 1586, 1640, 2840, 2929; ¹H NMR (C₂D₆CO, 300 MHz) δ (ppm) 3.38 (s, 3H), 3.44 (s, 3H), 3.70 (s, 3H), 6.74 – 6.76 (m, 2H), 6.79 – 6.80 (m, 1H), 7.15 – 7.20 (m, 2H), 7.31 (t, *J* = 8 Hz, 1H), 7.39 – 7.43 (m, 4H), 7.49 – 7.52 (m, 2H); ¹³C NMR (C₂D₆CO, 75 MHz) δ (ppm) 21.5, 38.4, 55.7, 113.0, 113.9, 120.2, 124.9, 126.9, 128.5, 129.4, 129.8, 130.1, 130.7, 136.6, 137.4, 140.9, 142.9, 147.5, 161.3, 170.3.

3'-(Dimethylamino)-N-(3-methoxyphenyl)-N-methyl-[1,1'-biphenyl]-4-carboxamide (15a) The title compound was prepared by reaction of 4-bromo-*N*-(3-methoxyphenyl)-*N*-methylbenzamide (**6b**) (80 mg, 0.25mmol), 3-(dimethylamino)phenylboronic acid (54 mg, 0.33mmol), cesium carbonate (244 mg, 0.75mmol) and tetrakis(triphenyl)phosphine palladium (0.02 eq., 6 mg) in DME/EtOH/H₂O (1/1/1, 3 mL) according to method B. The residue was purified by silica gel column chromatography (hexanes/EtOAc70:30) to afford the desired product as yellow oil (49 mg, 54 %). C₂₃H₂₄N₂O₂; MW 360; MS (ESI) 361 [M+H]⁺; IR (cm⁻¹) 1597, 1639, 2797, 2834, 2939; ¹H NMR (C₂D₆CO, 300 MHz) δ (ppm) 2.97 (s, 6H), 3.43 (s, 3H), 3.70 (s, 3H), 6.72 – 6.76 (m, 3H), 6.79 – 6.80 (m, 1H), 6.86 – 6.93 (m, 2H), 7.17 (t, *J* = 8.0 Hz, 1H), 7.23 (t, *J* = 8.0 Hz, 1H), 7.38 – 7.41 (m, 2H), 7.49 – 7.52 (m, 2H); ¹³C NMR (C₂D₆CO, 75 MHz) δ (ppm) 38.5, 40.8, 55.7, 111.8, 113.0, 113.9, 116.0, 120.2, 127.0, 130.0, 130.4, 130.7, 136.5, 141.6, 143.9, 147.5, 152.2, 161.3, 170.4.

***N*-(3-methoxyphenyl)-*N*,3',4'-trimethyl-[1,1'-biphenyl]-4-carboxamide (17a)** The title compound was prepared by reaction of 4-bromo-*N*-(3-methoxyphenyl)-*N*-methylbenzamide (**6b**) (100 mg, 0.31mmol), 3,4-dimethylphenylboronic acid (62 mg, 0.41mmol), cesium carbonate (303 mg, 0.93mmol) and tetrakis(triphenyl)phosphine palladium (0.02 eq., 7 mg) in DME/EtOH/H₂O (1/1/1, 3 mL) according to method B. The residue was purified by silica gel column chromatography (hexanes/EtOAc70:30) to afford the desired product as yellow oil (106 mg, 99 %). C₂₃H₂₃NO₂; MW 345; MS (ESI) 346[M+H]⁺; IR (cm⁻¹) 1599, 1640, 2840, 2914, 2942; ¹H NMR (C₂D₆CO, 500 MHz) δ (ppm) 2.26 (s, 3H), 2.29 (s, 3H), 3.43 (s, 3H), 3.70 (s, 3H), 6.73 – 6.75 (m, 2H), 6.79 – 6.80 (m, 1H), 7.15 – 7.19 (m, 2H), 7.32 (dd, *J* = 2.0Hz, 8.0Hz, 1H), 7.38 – 7.40 (m, 3H), 7.47 – 7.49 (m, 2H); ¹³C NMR (C₂D₆CO, 125 MHz) δ (ppm) 19.4, 19.8, 38.4, 55.6, 112.9, 113.8, 120.1, 125.0, 126.5, 128.8, 130.0, 130.6, 131.0, 136.2, 137.0, 137.8, 138.3, 142.8, 147.4, 161.2, 170.3.

3',4'-Difluoro-*N*-(3-methoxyphenyl)-*N*-methyl-[1,1'-biphenyl]-4-carboxamide (18a) The title compound was prepared by reaction of 4-bromo-*N*-(3-methoxyphenyl)-*N*-methylbenzamide (**6b**) (100 mg, 0.31mmol), 3,4-difluorophenylboronic acid (65 mg, 0.41mmol), cesium carbonate (303 mg, 0.93mmol) and tetrakis(triphenyl)phosphine palladium (0.02 eq., 7 mg) in DME/EtOH/H₂O (1/1/1, 3 mL) according to method B. The residue was purified by silica gel column chromatography (hexanes/EtOAc70:30) to afford the desired product as yellow oil (97 mg, 88 %). C₂₁H₁₇F₂NO₂; MW 353; MS (ESI) 354[M+H]⁺; IR (cm⁻¹) 1599, 1639, 2837, 2948; ¹H NMR (C₂D₆CO, 500 MHz) δ (ppm) 3.43 (s, 3H), 3.70 (s, 3H), 6.73 – 6.76 (m, 2H), 6.80 – 6.81 (m, 1H), 7.17 (t, *J* = 8.0 Hz, 1H), 7.35 – 7.41 (m, 1H), 7.42 – 7.44 (m, 2H), 7.45 – 7.48 (m, 1H), 7.52 – 7.54 (m, 2H), 7.56 (dd, *J* = 2.0 Hz, 8.0 Hz, 1H), 7.60 (dd, *J* = 2.0 Hz, 8.0 Hz, 1H); ¹³C NMR (C₂D₆CO, 125 MHz) δ (ppm) 38.3, 55.7, 113.0, 113.8, 116.6, 116.7, 118.5, 118.7, 120.2, 124.3, 124.4, 126.9, 130.1, 130.7, 137.3, 140.3, 147.3, 161.2, 170.0.

3',4'-Dimethoxy-*N*-(3-methoxyphenyl)-*N*-methyl-[1,1'-biphenyl]-4-carboxamide (16a) The title compound was prepared by reaction of 4-bromo-*N*-(3-methoxyphenyl)-*N*-methylbenzamide (**6b**) (100 mg, 0.31mmol), 3,4-dimethoxyphenylboronic acid (75 mg, 0.41mmol), cesium carbonate (303 mg, 0.93mmol) and tetrakis(triphenyl)phosphine palladium (0.02 eq., 7 mg) in DME/EtOH/H₂O (1/1/1, 3 mL) according to method B. The residue was purified by silica gel column chromatography (hexanes/EtOAc70:30) to afford the desired product as white solid (83 mg, 71 %).

C₂₃H₂₃NO₄; MW 377; mp: 153 – 156°C; MS (ESI) 378[M+H]⁺; IR (cm⁻¹) 1604, 1635, 2843, 2938, 2969, 3003, 3068; ¹H NMR (C₂D₆CO, 300 MHz) δ (ppm) 3.51 (s, 3H), 3.69 (s, 3H), 3.90 (s, 3H), 3.92 (s, 3H), 6.62 – 6.72 (m, 3H), 6.89 – 6.91 (d, *J* = 8.0 Hz, 1H), 7.04 – 7.17 (m, 3H), 7.38 (s, 4H); ¹³C NMR (C₂D₆CO, 75 MHz) δ (ppm) 38.6, 55.6, 56.1, 110.4, 111.6, 112.2, 113.0, 119.4, 119.6, 126.1, 129.4, 130.0, 133.2, 134.4, 142.2, 146.3, 149.2, 149.3, 160.2, 170.5.

2'-Fluoro-3'-methoxy-*N*-(3-methoxyphenyl)-*N*-methyl-[1,1'-biphenyl]-4-carboxamide (19a)

The title compound was prepared by reaction of 4-bromo-*N*-(3-methoxyphenyl)-*N*-methylbenzamide (**6b**) (80 mg, 0.25mmol), 2-fluoro-3-methoxyphenylboronic acid (56 mg, 0.33mmol), cesium carbonate (244 mg, 0.75mmol) and tetrakis(triphenyl)phosphine palladium (0.02 eq., 6 mg) in DME/EtOH/H₂O (1/1/1, 3 mL) according to method B. The residue was purified by silica gel column chromatography (hexanes/EtOAc 90:10) to afford the desired product as brown solid (43 mg, 47 %). C₂₂H₂₀FNO₃; MW 365; mp: 125 – 127°C; MS (ESI) 366[M+H]⁺; IR (cm⁻¹) 1592, 1644, 2837, 2948, 2975, 3009; ¹H NMR (C₂D₆CO, 300 MHz) δ (ppm) 3.44 (s, 3H), 3.70 (s, 3H), 3.90 (s, 3H), 6.72 – 6.81 (m, 3H), 6.95 – 7.00 (m, 1H), 7.10 – 7.20 (m, 3H), 7.39 – 7.45 (m, 4H); ¹³C NMR (C₂D₆CO, 75 MHz) δ (ppm) 38.3, 55.7, 56.6, 113.1, 113.8, 113.9, 120.1, 122.4, 125.2, 125.3, 129.0, 129.1, 129.6, 130.6, 137.1, 137.5, 147.3, 161.2, 170.1.

2'-Fluoro-*N*-(3-methoxyphenyl)-*N*,3'-dimethyl-[1,1'-biphenyl]-4-carboxamide (20a) The title compound was prepared by reaction of 4-bromo-*N*-(3-methoxyphenyl)-*N*-methylbenzamide (**6b**) (72 mg, 0.22mmol), 2-fluoro-3-methylphenylboronic acid (45 mg, 0.29mmol), cesium carbonate (215 mg, 0.66mmol) and tetrakis(triphenyl)phosphine palladium (0.02 eq., 5 mg) in DME/EtOH/H₂O (1/1/1, 3 mL) according to method B. The residue was purified by silica gel column chromatography (hexanes/EtOAc70:30) to afford the desired product as yellow solid (70 mg, 91 %). C₂₂H₂₀FNO₂; MW 349; mp: 91 – 94°C; MS (ESI) 350 [M+H]⁺; IR (cm⁻¹) 1599, 1635, 2840, 2920, 2963, 3055; ¹H NMR (C₂D₆CO, 500 MHz) δ (ppm) 2.29 (d, *J* = 2.5 Hz, 3H), 3.44 (s, 3H), 3.70 (s, 3H), 6.73 – 6.77 (m, 2H), 6.79-6.80 (m, 1H), 7.13 (t, *J* = 8.0 Hz, 1H), 7.18 (t, *J* = 8.0 Hz, 1H), 7.25 (t, *J* = 8.0 Hz, 1H), 7.39 – 7.44 (m, 4H); ¹³C NMR (C₂D₆CO, 125 MHz) δ (ppm) 14.6, 14.7, 38.3, 55.7, 113.1, 113.8, 120.1, 125.0, 125.1, 126.2, 126.3, 128.6, 128.7, 129.0, 129.07, 129.09, 129.6, 130.6, 131.9, 132.0, 137.0, 137.9, 147.3, 157.9, 159.9, 170.1.

4-(Benzo[d][1,3]dioxol-5-yl)-*N*-(3-methoxyphenyl)-*N*-methylbenzamide (22a) The title compound was prepared by reaction of 4-bromo-*N*-(3-methoxyphenyl)-*N*-methylbenzamide (**6b**) (80 mg, 0.25mmol), benzo[d][1,3]dioxol-5-ylboronic acid (55 mg, 0.33mmol), cesium carbonate (244 mg, 0.75mmol) and tetrakis(triphenyl)phosphine palladium (0.02 eq., 6 mg) in DME/EtOH/H₂O (1/1/1, 3 mL) according to method B. The residue was purified by silica gel column chromatography (hexanes/EtOAc70:30) to afford the desired product as yellow solid (68 mg, 76 %). C₂₂H₁₉NO₄; MW 361; mp: 139 – 141°C; MS (ESI) 362 [M+H]⁺; IR (cm⁻¹) 1592, 1644, 2837, 2948, 2975, 3009; ¹H NMR (C₂D₆CO, 500 MHz) δ (ppm) 3.43 (s, 3H), 3.70 (s, 3H), 6.02 (s, 2H), 6.72 – 6.73 (m, 1H), 6.74 – 6.75 (m, 1H), 6.79 – 6.80 (m, 1H), 6.89 – 6.90 (m, 1H), 7.10 – 7.12 (m, 2H), 7.17 (t, *J* = 8.0 Hz, 1H), 7.37 – 7.39 (m, 2H), 7.44 – 7.46 (m, 2H); ¹³C NMR (C₂D₆CO, 125 MHz) δ (ppm) 38.4, 55.7, 102.3, 108.0, 109.4, 112.9, 113.8, 120.1, 121.4, 126.5, 130.0, 130.6, 135.0, 136.2, 142.4, 147.4, 148.5, 149.3, 161.2, 170.2.

3'-Methoxy-*N*-(4-methoxyphenyl)-*N*-methyl-[1,1'-biphenyl]-4-carboxamide (11a) The title compound was prepared by reaction of 4-bromo-*N*-(4-methoxyphenyl)-*N*-methylbenzamide (**11b**) (100 mg, 0.31mmol), 3-methoxyphenylboronic acid (61 mg, 0.40mmol), cesium carbonate (303 mg, 0.93mmol) and tetrakis(triphenyl)phosphine palladium (0.02 eq., 7 mg) in DME/EtOH/H₂O (1/1/1, 3 mL) according to method B. The residue was purified by silica gel column chromatography (hexanes/EtOAc70:30) to afford the desired product as colorless oil (106 mg, 98 %). C₂₂H₂₁NO₃; MW 347; MS (ESI) 348 [M+H]⁺; IR (cm⁻¹) 1635, 2840, 2935; ¹H NMR (C₂D₆CO, 300 MHz) δ (ppm) 3.40 (s, 3H), 3.75 (s, 3H), 3.85 (s, 3H), 6.82 – 6.86 (m, 2H), 6.92 (ddd, *J* = 1.0 Hz, 2.6 Hz, 8.3 Hz, 1H), 7.12 – 7.19 (m, 4H), 7.32 – 7.40 (m, 3H), 7.50 – 7.53 (m, 2H); ¹³C NMR (C₂D₆CO, 75 MHz) δ (ppm) 38.7, 55.6, 55.7, 113.1, 114.3, 115.2, 120.0, 126.9, 129.2, 130.1, 130.8, 136.9, 139.0, 142.2, 142.3, 159.0, 161.2, 170.2.

4'-Methoxy-*N*-(4-methoxyphenyl)-*N*-methyl-[1,1'-biphenyl]-4-carboxamide (12a) The title compound was prepared by reaction of 4-bromo-*N*-(4-methoxyphenyl)-*N*-methylbenzamide (**11b**) (78 mg, 0.24mmol), 4-methoxyphenylboronic acid (48 mg, 0.32mmol), cesium carbonate (235 mg, 0.72mmol) and tetrakis(triphenyl)phosphine palladium (0.02 eq., 6 mg) in DME/EtOH/H₂O (1/1/1, 3 mL) according to method B. The residue was purified by silica gel column chromatography (hexanes/EtOAc 90:10) to afford the desired product as yellow solid (73 mg, 88 %). C₂₂H₂₁NO₃; MW 347; mp: 129 – 132°C; MS (ESI) 348 [M+H]⁺; IR (cm⁻¹) 1635, 2840, 2932, 2957; ¹H NMR (C₂D₆CO, 300 MHz) δ (ppm) 3.39 (s, 3H), 3.74 (s, 3H), 3.83 (s, 3H), 6.82 – 6.82 (m, 2H), 6.98 – 7.01 (m, 2H), 7.11 – 7.14 (m, 2H), 7.34 – 7.37 (m, 2H), 7.44 – 7.47 (m, 2H), 7.54 – 7.57 (m, 2H); ¹³C NMR (C₂D₆CO, 75 MHz) δ (ppm) 38.7, 55.6, 55.7, 115.2, 126.2, 128.8, 129.2, 130.2, 133.0, 135.9, 139.1, 142.1, 159.0, 160.6, 170.3.

3'-Methoxy-*N*-methyl-*N*-(*m*-tolyl)-[1,1'-biphenyl]-4-carboxamide (5a) The title compound was prepared by reaction of 4-bromo-*N*-(3-methylphenyl)-*N*-methylbenzamide (**5b**) (123 mg, 0.40mmol), 3-methoxyphenylboronic acid (79 mg, 0.52mmol), cesium carbonate (393 mg, 1.20mmol) and tetrakis(triphenyl)phosphine palladium (0.02 eq., 9 mg) in DME/EtOH/H₂O (1/1/1, 3 mL) according to method B. The residue was purified by silica gel column chromatography (hexanes/EtOAc70:30) to afford the desired product as yellow oil (101 mg, 77 %). C₂₂H₂₁NO₂; MW 331; MS (ESI) 332 [M+H]⁺; IR (cm⁻¹) 1582, 1601, 1639, 2834, 2935, 3034; ¹H NMR (C₂D₆CO, 300 MHz) δ (ppm) 2.24 (s, 3H), 3.42 (s, 3H), 3.84 (s, 3H), 6.90 – 7.00 (m, 3H), 7.08 (s, 1H), 7.11 – 7.18 (m, 3H), 7.33 (t, *J* = 8.0 Hz, 1H), 7.38 – 7.41 (m, 2H), 7.49 – 7.52 (m, 2H); ¹³C NMR (C₂D₆CO, 75 MHz) δ (ppm) 21.2, 38.5, 55.6, 113.1, 114.3, 120.0, 125.1, 126.9, 127.9, 128.4, 129.8, 130.1, 130.8, 136.7, 139.9, 142.3, 142.5, 146.2, 161.2, 170.2.

2'-Fluoro-*N*,3'-dimethyl-*N*-(*m*-tolyl)-[1,1'-biphenyl]-4-carboxamide (21a) The title compound was prepared by reaction of 4-bromo-*N*-(3-methylphenyl)-*N*-methylbenzamide (**5b**) (93 mg, 0.31mmol), 2-fluoro-3-methylphenylboronic acid (62 mg, 0.40mmol), cesium carbonate (303 mg, 0.93mmol) and tetrakis(triphenyl)phosphine palladium (0.02 eq., 7 mg) in DME/EtOH/H₂O (1/1/1, 3 mL) according to method B. The residue was purified by silica gel column chromatography (hexanes/EtOAc70:30) to afford the desired product as white solid (103 mg, quantitative). C₂₂H₂₀FNO; MW 333; mp: 73 – 76°C; MS (ESI) 334 [M+H]⁺; IR (cm⁻¹) 1604, 1634, 2853, 2920; ¹H NMR (C₂D₆CO, 500 MHz) δ (ppm) 2.24 (s, 3H), 2.28 (d, *J* = 2.4 Hz, 3H), 3.43 (s, 3H), 6.94 – 6.97 (m, 1H), 6.98 – 7.01 (m, 1H), 7.07 (s, 1H), 7.11 – 7.16 (m, 2H), 7.23 – 7.26 (m, 2H), 7.38 – 7.41

(m, 4H); ^{13}C NMR ($\text{C}_2\text{D}_6\text{CO}$, 125 MHz) δ (ppm) 14.6, 14.7, 21.2, 38.5, 125.05, 125.09, 125.12, 126.2, 126.3, 128.5, 128.6, 128.7, 128.99, 129.01, 129.07, 129.09, 129.6, 129.8, 131.9, 132.0, 136.9, 137.8, 139.9, 146.1, 157.9, 159.9, 170.1.

4-(Benzo[d][1,3]dioxol-5-yl)-*N*-methyl-*N*-(*m*-tolyl)benzamide (22a) The title compound was prepared by reaction of 4-bromo-*N*-(3-methylphenyl)-*N*-methylbenzamide (**5b**) (79 mg, 0.26mmol), benzo[d][1,3]dioxol-5-ylboronic acid (56 mg, 0.34mmol), cesium carbonate (254 mg, 0.78mmol) and tetrakis(triphenyl)phosphine palladium (0.02 eq., 6 mg) in DME/EtOH/H₂O (1/1/1, 3 mL) according to method B. The residue was purified by silica gel column chromatography (hexanes/EtOAc70:30) to afford the desired product as yellow solid (44 mg, 49 %). $\text{C}_{22}\text{H}_{19}\text{NO}_3$; MW 345; mp: 111 – 113°C; MS (ESI) 346[M+H]⁺; IR (cm^{-1}) 1602, 1634, 2788, 2911, 2966; ^1H NMR ($\text{C}_2\text{D}_6\text{CO}$, 500 MHz) δ (ppm) 2.24 (s, 3H), 3.42 (s, 3H), 6.02 (s, 2H), 6.89 (d, $J = 8.0$ Hz, 1H), 6.94 (d, $J = 8.0$ Hz, 1H), 6.99 (d, $J = 8.0$ Hz, 1H), 7.07 – 7.11 (m, 3H), 7.14 (t, $J = 8.0$ Hz, 1H), 7.35 – 7.37 (m, 2H), 7.42 – 7.44 (m, 2H); ^{13}C NMR ($\text{C}_2\text{D}_6\text{CO}$, 125 MHz) δ (ppm) 21.2, 38.5, 102.3, 107.9, 109.4, 121.4, 125.1, 126.5, 127.9, 128.4, 129.8, 130.2, 135.1, 136.2, 139.9, 142.3, 146.3, 148.5, 149.3, 170.2.

2'-Fluoro-*N*-(3-methoxybenzyl)-*N*,3'-dimethyl-[1,1'-biphenyl]-4-carboxamide (25a) The title compound was prepared by reaction of 4-bromo-*N*-(3-methoxybenzyl)-*N*-methylbenzamide (**25b**) (200 mg, 0.60mmol), 2-fluoro-3-methylphenylboronic acid (120 mg, 0.78mmol), cesium carbonate (587 mg, 1.80mmol) and tetrakis(triphenyl)phosphine palladium (0.02 eq., 14 mg) in DME/EtOH/H₂O (1/1/1, 3 mL) according to method B. The residue was purified by silica gel column chromatography (hexanes/EtOAc70:30) to afford the desired product as yellow oil (200 mg, 87 %). $\text{C}_{23}\text{H}_{22}\text{FNO}_2$; MW 363; MS (ESI) 364 [M+H]⁺; IR (cm^{-1}) 1630, 2834, 2923, 3034; ^1H NMR ($\text{C}_2\text{D}_6\text{CO}$, 500 MHz) δ (ppm) 2.32 (s, 3H), 2.97 (s, 3H), 3.81 (s, 3H), 4.59 – 4.73 (m, 2H), 6.80 – 7.00 (m, 3H), 7.17 (t, $J = 8$ Hz, 1H), 7.27 – 7.32 (m, 2H), 7.33-7.36 (m, 1H), 7.57 – 7.59 (m, 2H), 7.62 (s, 2H); ^{13}C NMR ($\text{C}_2\text{D}_6\text{CO}$, 125 MHz) δ (ppm) 14.6, 14.7, 37.3, 51.0, 55.5, 113.6, 114.4, 121.0, 125.1, 125.2, 126.2, 126.3, 128.1, 128.7, 128.8, 129.1, 129.2, 129.7, 129.8, 130.5, 132.0, 132.1, 137.1, 138.0, 158.0, 159.9, 161.1.

2'-Fluoro-*N*-(3-hydroxybenzyl)-*N*,3'-dimethyl-[1,1'-biphenyl]-4-carboxamide (25) To a solution of 2'-fluoro-*N*-(3-methoxybenzyl)-*N*,3'-dimethyl-[1,1'-biphenyl]-4-carboxamide (**25a**) (100 mg, 0.28mmol) in CH_2Cl_2 (10 mL) was added trifluorobromine dimethyl sulphide complex $\text{BF}_3 \cdot \text{SMe}_2$ (0.18 mL, 1.68mM) at room temperature. The reaction mixture was stirred overnight. The reaction was quenched with MeOH (10 mL). The solvent was removed under reduced pressure at 25°C. Water was added to dissolve inorganic salts and the precipitated was filtered off and triturated with diethyl ether to afford the desired product as yellow solid (66 mg, 67 %). $\text{C}_{22}\text{H}_{20}\text{FNO}_2$; MW 349; mp: 123 – 126°C; MS (ESI) 350 [M+H]⁺; IR (cm^{-1}) 1600, 2917, 3181; ^1H NMR ($\text{C}_2\text{D}_6\text{CO}$, 500 MHz) δ (ppm) 2.32 (s, 3H), 2.96 (s, 3H), 4.55 – 4.69 (m, 2H), 6.72 – 6.90 (m, 3H), 7.16 – 7.22 (m, 2H), 7.29 (t, $J = 8.0$ Hz, 1H), 7.33 – 7.36 (m, 1H), 7.57 – 7.58 (m, 2H), 7.62 (s, 2H); ^{13}C NMR ($\text{C}_2\text{D}_6\text{CO}$, 75 MHz) δ (ppm) 14.6, 14.7, 115.2, 125.1, 125.2, 126.2, 126.4, 128.0, 128.7, 128.9, 129.17, 129.21, 129.7, 129.8, 130.6, 132.0, 132.1, 137.0, 138.0, 157.3, 158.6, 160.6

3-Methoxy-*N*-(3'-methoxy-[1,1'-biphenyl]-4-yl)-*N*-methylbenzamide (24a) The title compound was prepared by reaction of *N*-(4-bromophenyl)-3-methoxy-*N*-methylbenzamide (**24b**) (80

mg, 0.25 mmol), 3-methoxyphenylboronic acid (50 mg, 0.33 mmol), cesium carbonate (244 mg, 0.75 mmol) and tetrakis(triphenylphosphine) palladium (0.02 eq., 6 mg) in DME/EtOH/H₂O (1/1/1, 3 mL) according to method B. The residue was purified by silica gel column chromatography (hexanes/EtOAc 70:30) to afford the desired product as yellow oil (59 mg, 68 %). C₂₂H₂₁NO₃; MW 347; MS (ESI) 348 [M+H]⁺; IR (cm⁻¹) 1640, 2840, 2936; ¹H NMR (C₂D₆CO, 300 MHz) δ (ppm) 3.45 (s, 3H), 3.66 (s, 3H), 3.85 (s, 3H), 6.80–6.84 (m, 1H), 6.90–6.94 (m, 3H), 7.09–7.19 (m, 3H), 7.24–7.27 (m, 2H), 7.34 (t, *J* = 8.0 Hz, 1H), 7.57–7.60 (m, 2H); ¹³C NMR (C₂D₆CO, 75 MHz) δ (ppm) 38.4, 55.6, 55.7, 113.2, 114.0, 114.9, 116.4, 120.0, 121.9, 128.3, 128.4, 129.7, 130.9, 139.0, 139.6, 142.3, 145.7, 160.1, 161.3, 170.3.

Biological methods

[2,4,6,7-³H]-E2 and [2,4,6,7-³H]-E1 were purchased from Perkin-Elmer, Boston. Quickszint Flow 302 scintillator fluid was bought from Zinsser Analytic, Frankfurt. Other chemicals were purchased from Sigma, Roth or Merck.

h17β-HSD1 and *h17β*-HSD2 enzyme preparation

Cytosolic (*h17β*-HSD1) and microsomal (*h17β*-HSD2) fractions were obtained from human placenta according to previously described procedures [21, 28]. Fresh tissue was homogenized and the enzymes were separated from the mitochondria, cell membrane. Nucleus and other rests by fractional centrifugation at 1000 g, 10.000 g and 150.000 g. The pellet fraction containing the microsomal *h17β*-HSD2 was used for the determination of *h17β*-HSD2 inhibition, while *h17β*-HSD1 was obtained after precipitation with ammonium sulfate from the cytosolic fraction for use of testing of *h17β*-HSD1 inhibition. Aliquots containing *h17β*-HSD1 or *h17β*-HSD2 were stored frozen.

m17β-HSD2 enzyme preparation and inhibition

The microsomal fraction (*m17β*-HSD2) was obtained from mouse liver as described for *h17β*-HSD2. Inhibitory activities were evaluated by a method identical to the one described for the human enzyme.

m17β-HSD1 enzyme preparation

Recombinant *m17β*-HSD1 enzyme was produced by transfection of HEK 293 cells with a *m17β*-HSD1 expression plasmid (coding sequence of NM_010475 in pCMV6Entry vector, OriGene Technologies, Inc.) according to a described procedure [29]. 48 hours after transfection cells were homogenized by sonication (3 x 10 s) in a buffer containing saccharose (40 mM Tris, 250 mM saccharose, 5 mM EDTA, 7 mM DTT, 1 mM PMSF, pH 7.5). Cell lysate was centrifuged (1000 g, 15 min, 4°C) and 20% glycerol was added to the supernatant before aliquots were frozen and stored at -70°C.

Inhibition of *h17β*-HSD2 and *m17β*-HSD2 in cell-free assay

Inhibitory activities were evaluated following an established method with minor modifications [30–32]. Briefly, the enzyme preparation was incubated with NAD⁺ [1500 μM] in the presence of potential inhibitors at 37 °C in a phosphate buffer (50 mM) supplemented with 20% of glycerol and EDTA 1 mM. Inhibitor stock solutions were prepared in DMSO. Final concentration of DMSO was adjusted to 1% in all samples. The enzymatic reaction was started by addition of a mixture of unlabelled- and [³H]-E2 (final concentration: 500 nM, 0.11 μCi). After 20 min, the incubation was stopped with HgCl₂ and the mixture was extracted with ether. After evaporation, the steroids were dissolved in acetonitrile/water (45:55). E1 and E2 were separated using acetonitrile/water (45:55) as mobile phase in a C18 RP chromatography column (Nucleodur C18, 3 μm, Macherey-Nagel, Düren)

connected to a HPLC-system (Agilent 1100 Series, Agilent Technologies, Waldbronn). Detection and quantification of the steroids were performed using a radioflow detector (Berthold Technologies, Bad Wildbad). The conversion rate was calculated according to the following equation: %conversion = $(\%E1/(\%E1+\%E2)) \times 100$. Each value was calculated from at least two independent experiments.

Inhibition of *h17β*-HSD1 in cell-free assay

The *17β*-HSD1 inhibition assay was performed similarly to the *h17β*-HSD2 test. The human cytosolic enzyme was incubated with NADH [500 μM] while the mouse recombinant enzyme was reacted with NADPH [500 μM]. Test compound and a mixture of unlabelled- and [³H]-E1 (final concentration: 500 nM, 0.15 μCi) were added and mixed for 10 min at 37°C. Further treatment of the samples and HPLC separation was carried out as mentioned above for *h17β*-HSD2.

Inhibition of *h17β*-HSD2 in a cellular assay

Cellular *h17β*-HSD2 inhibitory activity is measured using the breast cancer cell-line MDA-MB-231[33] (*17β*-HSD1 activity negligible). [³H]-E2 (200 nM) is taken as substrate and is incubated with the inhibitor for 6 h at 37 °C. After ether extraction, substrate and product are separated by HPLC and detected with a radioflow detector. Potency is evaluated as percentage of inhibition (inhibitor concentrations used: 1250 nM and 250 nM).

Estrogen receptor affinity in a cell-free assay

The binding affinity of selected compounds to ER α and ER β was determined according to the recommendations of the US Environmental Protection Agency (EPA) by their Endocrine Disruptor Screening Program (EDSP)[25] using recombinant human proteins. Briefly, 1 nM of ER α and 4 nM of ER β , respectively, were incubated with [³H]-E2 (3 nM for ER α and 10 nM for ER β) and test compound for 16-20 h at 4°C.

The potential inhibitors were dissolved in DMSO (5% final concentration). Evaluation of non-specific-binding was performed with unlabeled E2 at concentrations 100-fold of [³H]-E2 (300 nM for ER α and 1000 nM for ER β). After incubation, ligand-receptor complexes were selectively bound to hydroxyapatite (83.5 g/LinTE-buffer). The bound complex was washed three times and resuspended in ethanol. For radiodetection, scintillator cocktail (Quickszint 212, Zinsser Analytic, Frankfurt) was added and samples were measured in a liquid scintillation counter (1450 LSC & Luminescence Counter, Perkin Elmer).

From these results the percentage of [³H]-E2 displacement by the compounds was calculated. The plot of % displacement versus compound concentration resulted in sigmoidal binding curves. The compound concentrations necessary to displace 50% of the receptor bound [³H]-E2 were determined. Unlabeled E2 IC₅₀ values were determined in each experiment and used as reference. The E2 IC₅₀ determined were 3±20% nM for ER α and 10±20% nM for ER β .

Relative Binding Affinity was determined by applying the following equation: RBA[%] = $(IC_{50}(E2)/IC_{50}(\text{compound})) \cdot 100$ [25]. This results in a RBA value of 100% for E2.

After the assay was established and validated, a modification was made to increase throughput. Compounds were tested at concentrations of 1000 times the IC₅₀(E2). Compounds with less than 50% displacement of [³H]-E2 at a concentration of 1000 times IC₅₀(E2) were classified as RBA <0.1%.

Metabolic Stability in a cell-free assay

Compounds **7a**, **8a**, **16a**, **19a**, **22a**, **27a** and **27** were tested according to established method[34-36] For evaluation of phase I and II metabolic stability 1 μM compound was incubated with 1 mg/ml pooled mammalian liver S9 fraction (BD Gentest), 2 mM NADPH regenerating system, 1 mM UDPGA and 0.1 mM PAPS at 37°C for 0, 5, 15 and 60 minutes at a final volume of 100 μL. The

incubation was stopped by precipitation of S9 enzymes with 2 volumes of cold acetonitrile containing internal standard. Concentration of the remaining test compound at the different time points was analyzed by LC-MS/MS and used to determine half-life ($t_{1/2}$).

ACKNOWLEDGMENT

We thank Josef Zapp for the NMR measurements, Larissa Müller, Isabella Mang and Martina Jankowski for the biological tests.

REFERENCES

1. Osteoporosis prevention, diagnosis, and therapy. 2001; 285: 785-795.
2. Vanderschueren D, Gaytant J, Boonen S and Venken K. Androgens and bone. 2008; 15: 250-254.
3. Wu L, Einstein M, Geissler WM, Chan HK, Elliston KO, et al. Expression cloning and characterization of human 17 beta-hydroxysteroid dehydrogenase type 2, a microsomal enzyme possessing 20 alpha-hydroxysteroid dehydrogenase activity. 1993; 268: 12964-12969.
4. Dong Y, Qiu QQ, Debear J, Lathrop WF, Bertolini DR, et al. 17Beta-hydroxysteroid dehydrogenases in human bone cells. 1998; 13: 1539-1546.
5. Bydal P, Auger S and Poirier D. Inhibition of type 2 17beta-hydroxysteroid dehydrogenase by estradiol derivatives bearing a lactone on the D-ring: structure-activity relationships. 2004; 69: 325-342.
6. Poirier D, Bydal P, Tremblay MR, Sam KM and Luu-The V. Inhibitors of type II 17beta-hydroxysteroid dehydrogenase. 2001; 171: 119-128.
7. Sam KM, Auger S, Luu-The V and Poirier D. Steroidal spiro-gamma-lactones that inhibit 17 beta-hydroxysteroid dehydrogenase activity in human placental microsomes. 1995; 38: 4518-4528.
8. Gunn D, Akuche C, Baryza J, Blue ML, Brennan C, et al. 4,5-Disubstituted cis-pyrrolidinones as inhibitors of type II 17beta-hydroxysteroid dehydrogenase. Part 2. SAR. 2005; 15: 3053-3057.
9. Wood J, Bagi CM, Akuche C, Bacchiocchi A, Baryza J, et al. 4,5-Disubstituted cis-pyrrolidinones as inhibitors of type II 17beta-hydroxysteroid dehydrogenase. Part 3. Identification of lead candidate. 2006; 16: 4965-4968.
10. Wetzel M, Marchais-Oberwinkler S, Perspicace E, Moller G, Adamski J, et al. Introduction of an electron withdrawing group on the hydroxyphenyl naphthol scaffold improves the potency of 17beta-hydroxysteroid dehydrogenase type 2 (17beta-HSD2) inhibitors. 2011; 54: 7547-7557.
11. Wetzel M, Gargano EM, Hinsberger S, Marchais-Oberwinkler S and Hartmann RW. Discovery of a new class of bicyclic substituted hydroxyphenylmethanones as 17beta-hydroxysteroid dehydrogenase type 2 (17beta-HSD2) inhibitors for the treatment of osteoporosis. 2012; 47: 1-17.
12. Marchais-Oberwinkler S, Xu K, Wetzel M, Perspicace E, Negri M, et al. Structural optimization of 2,5-thiophene amides as highly potent and selective 17beta-hydroxysteroid dehydrogenase type 2 inhibitors for the treatment of osteoporosis. 2013; 56: 167-181.
13. Gargano EM, Perspicace E, Hanke N, Carotti A, Marchais-Oberwinkler S, et al. Metabolic stability optimization and metabolite identification of 2,5-thiophene amide 17beta-hydroxysteroid dehydrogenase type 2 inhibitors. 2014; 87: 203-219.
14. Xu K, Al-Soud YA, Wetzel M, Hartmann RW and Marchais-Oberwinkler S. Triazole ring-opening leads to the discovery of potent nonsteroidal 17beta-hydroxysteroid dehydrogenase type 2 inhibitors. 2011; 46: 5978-5990.
15. Marchais-Oberwinkler S, Kruchten P, Frotscher M, Ziegler E, Neugebauer A, et al. Substituted 6-phenyl-2-naphthols. Potent and selective nonsteroidal inhibitors of 17beta-hydroxysteroid dehydrogenase type 1 (17beta-HSD1): design, synthesis, biological evaluation, and pharmacokinetics. 2008; 51: 4685-4698.
16. Bey E, Marchais-Oberwinkler S, Kruchten P, Frotscher M, Werth R, et al. Design, synthesis and biological evaluation of bis(hydroxyphenyl) azoles as potent and selective non-steroidal inhibitors of 17beta-

- hydroxysteroid dehydrogenase type 1 (17 β -HSD1) for the treatment of estrogen-dependent diseases. 2008; 16: 6423-6435.
17. Turner AS. Animal models of osteoporosis--necessity and limitations. 2001; 1: 66-81.
18. Reinwald S and Burr D. Review of nonprimate, large animal models for osteoporosis research. 2008; 23: 1353-1368.
19. U.S. Food and Drug Administration. Drug Development and Review Definitions 2015; Available: <http://www.fda.gov/drugs/developmentapprovalprocess/howdrugsaredevelopedandapproved/approvalapplications/investigationalnewdrugindapplication/ucm176522.htm>
20. Kruchten P, Werth R, Marchais-Oberwinkler S, Frotscher M and Hartmann RW. Development of a biological screening system for the evaluation of highly active and selective 17 β -HSD1-inhibitors as potential therapeutic agents. 2009; 301: 154-157.
21. Marchais-Oberwinkler S, Wetzel M, Ziegler E, Kruchten P, Werth R, et al. New drug-like hydroxyphenylnaphthol steroidmimetics as potent and selective 17 β -hydroxysteroid dehydrogenase type 1 inhibitors for the treatment of estrogen-dependent diseases. 2011; 54: 534-547.
22. Tremblay MR, Lin SX and Poirier D. Chemical synthesis of 16 β -propylaminoacyl derivatives of estradiol and their inhibitory potency on type 1 17 β -hydroxysteroid dehydrogenase and binding affinity on steroid receptors. 2001; 66: 821-831.
23. Perspicace E, Giorgio A, Carotti A, Marchais-Oberwinkler S and Hartmann RW. Novel N-methylsulfonamide and retro-N-methylsulfonamide derivatives as 17 β -hydroxysteroid dehydrogenase type 2 (17 β -HSD2) inhibitors with good ADME-related physicochemical parameters. 2013; 69: 201-215.
24. Kavanagh KL, Jornvall H, Persson B and Oppermann U. Medium- and short-chain dehydrogenase/reductase gene and protein families : the SDR superfamily: functional and structural diversity within a family of metabolic and regulatory enzymes. 2008; 65: 3895-3906.
25. U.S. Environmental Protection Agency. Protocol for the In Vitro Estrogen Receptor Saturation Binding and Competitive Binding Assays Using Rat Uterine Cytosol 2015; Available: http://www.epa.gov/endo/pubs/assayvalidation/appendix1_er_ruc.pdf
26. Martignoni M, Groothuis GM and de Kanter R. Species differences between mouse, rat, dog, monkey and human CYP-mediated drug metabolism, inhibition and induction. 2006; 2: 875-894.
27. Lipinski CA, Lombardo F, Dominy BW and Feeney PJ. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. 2001; 46: 3-26.
28. Zhu DW, Lee X, Breton R, Ghosh D, Pangborn W, et al. Crystallization and preliminary X-ray diffraction analysis of the complex of human placental 17 β -hydroxysteroid dehydrogenase with NADP⁺. 1993; 234: 242-244.
29. Sam KM, Boivin RP, Tremblay MR, Auger S and Poirier D. C16 and C17 derivatives of estradiol as inhibitors of 17 β -hydroxysteroid dehydrogenase type 1: chemical synthesis and structure-activity relationships. 1998; 15: 157-180.
30. Xu KW, M.; Hartmann, R. W.; Marchais-Oberwinkler, S. . Synthesis and biological evaluation of spiro- δ -lactones as inhibitors of 17 β -hydroxysteroid dehydrogenase type 2 (17 β -HSD2). 2011; 8: 406-421.
31. Lin SX, Yang F, Jin JZ, Breton R, Zhu DW, et al. Subunit identity of the dimeric 17 β -hydroxysteroid dehydrogenase from human placenta. 1992; 267: 16182-16187.
32. Puranen TJ, Poutanen MH, Peltoketo HE, Vihko PT and Vihko RK. Site-directed mutagenesis of the putative active site of human 17 β -hydroxysteroid dehydrogenase type 1. 1994; 304 (Pt 1): 289-293.
33. Day JM, Tutill HJ, Newman SP, Purohit A, Lawrence HR, et al. 17 β -hydroxysteroid dehydrogenase Type 1 and Type 2: association between mRNA expression and activity in cell lines. 2006; 248: 246-249.
34. Di L, Kerns EH, Hong Y, Kleintop TA, McConnell OJ, et al. Optimization of a higher throughput microsomal stability screening assay for profiling drug discovery candidates. 2003; 8: 453-462.
35. Moreno-Farre JW, P.; Raynud, F. Analysis of Potential Drug-Drug Interactions for Anticancer Agents in Human Liver Microsomes by High Throughput Liquid Chromatography/Mass Spectrometry Assay. 2007; 6: 55-69.
36. Hui JP, Stuart Grossert J, Cutler MJ and Melanson JE. Strategic identification of in vitro metabolites of 13-desmethyl spiroside C using liquid chromatography/high-resolution mass spectrometry. 2012; 26: 345-354.

